155 related articles for article (PubMed ID: 26116359)
1. Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.
Freiberger SN; Cheng PF; Iotzova-Weiss G; Neu J; Liu Q; Dziunycz P; Zibert JR; Dummer R; Skak K; Levesque MP; Hofbauer GF
Mol Cancer Ther; 2015 Sep; 14(9):2132-42. PubMed ID: 26116359
[TBL] [Abstract][Full Text] [Related]
2. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells.
Stahlhut M; Bertelsen M; Hoyer-Hansen M; Svendsen N; Eriksson AH; Lord JM; Scheel-Toellner D; Young SP; Zibert JR
J Drugs Dermatol; 2012 Oct; 11(10):1181-92. PubMed ID: 23134983
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Cytotoxicity against K562 Cells of 3-O-Angeloyl-20-O-acetyl Ingenol, a Derivative of Ingenol Mebutate.
Liu M; Chen F; Yu R; Zhang W; Han M; Liu F; Wu J; Zhao X; Miao J
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548156
[TBL] [Abstract][Full Text] [Related]
4. Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
Liang X; Grue-Sørensen G; Månsson K; Vedsø P; Soor A; Stahlhut M; Bertelsen M; Engell KM; Högberg T
Bioorg Med Chem Lett; 2013 Oct; 23(20):5624-9. PubMed ID: 23993332
[TBL] [Abstract][Full Text] [Related]
5. Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.
Woo YR; Lim JH; Jeong SW; Cho DH; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1012-1017. PubMed ID: 28370377
[TBL] [Abstract][Full Text] [Related]
6. Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel.
Segura S; Gadea A; Nonell L; Andrades E; Sánchez S; Pujol R; Hernández-Muñoz I; Toll A
PLoS One; 2020; 15(5):e0232146. PubMed ID: 32413042
[TBL] [Abstract][Full Text] [Related]
7. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
8. Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes.
Ulzii D; Kido-Nakahara M; Nakahara T; Tsuji G; Furue K; Hashimoto-Hachiya A; Furue M
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284553
[TBL] [Abstract][Full Text] [Related]
9. Ingenol mebutate-mediated reduction in p53-positive keratinocytes in skin cancerization field directly correlates with clinical response in patients with multiple actinic keratoses.
Grandi V; di Gennaro P; Torrigiani S; Basco L; Lastrucci I; Pimpinelli N
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1297-1303. PubMed ID: 30801837
[TBL] [Abstract][Full Text] [Related]
10. Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis.
Righi V; Tarentini E; Mucci A; Reggiani C; Rossi MC; Ferrari F; Casari A; Magnoni C
Sci Rep; 2019 Aug; 9(1):11515. PubMed ID: 31395965
[TBL] [Abstract][Full Text] [Related]
11. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.
Berman B
Clin Cosmet Investig Dermatol; 2012; 5():111-22. PubMed ID: 22956883
[TBL] [Abstract][Full Text] [Related]
12. Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Jedlowski PM
J Cutan Med Surg; 2023; 27(1):39-43. PubMed ID: 36495205
[TBL] [Abstract][Full Text] [Related]
13. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.
Cozzi SJ; Ogbourne SM; James C; Rebel HG; de Gruijl FR; Ferguson B; Gardner J; Lee TT; Larcher T; Suhrbier A
J Invest Dermatol; 2012 Apr; 132(4):1263-71. PubMed ID: 22189786
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
15. [Rapidly growing squamous cell carcinoma after ingenol mebutate treatment].
Ehret M; Velter C; Tebacher M; Bruant-Rodier C; Cribier B
Ann Dermatol Venereol; 2018 Oct; 145(10):607-612. PubMed ID: 29779859
[TBL] [Abstract][Full Text] [Related]
16. Contribution of extracellular signal-regulated kinase to UTP-induced interleukin-6 biosynthesis in HaCaT keratinocytes.
Kobayashi D; Ohkubo S; Nakahata N
J Pharmacol Sci; 2006 Dec; 102(4):368-76. PubMed ID: 17130674
[TBL] [Abstract][Full Text] [Related]
17. Repurposing of ingenol mebutate for treating human colorectal cancer by targeting S100 calcium-binding protein A4 (S100A4).
Hsieh YY; Cheng YW; Wei PL; Yang PM
Toxicol Appl Pharmacol; 2022 Aug; 449():116134. PubMed ID: 35724704
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
19. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
20. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
